Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Race Oncology Ltd. ( (AU:RAC) ).
Race Oncology Limited reported a 5.3% decrease in revenues from ordinary activities, amounting to $788,418 for the year ended 30 June 2025. Despite the revenue decline, the company significantly reduced its loss from ordinary activities after tax by 65.4% to $4,787,258 compared to the previous year. The company did not declare any dividends for the current or previous financial periods. Additionally, Race Oncology dissolved its wholly owned subsidiary in Belgium, Race Oncology SRL/BV, as part of its strategic operations, which may impact its international presence.
More about Race Oncology Ltd.
Race Oncology Limited operates in the biotechnology industry, focusing on the development and commercialization of cancer therapeutics. The company is primarily engaged in advancing its lead drug candidate, Bisantrene, which is targeted at treating various forms of cancer.
Average Trading Volume: 93,282
Technical Sentiment Signal: Sell
Current Market Cap: A$205M
See more data about RAC stock on TipRanks’ Stock Analysis page.